Suicide-related pediatric ED visits rose 74% from 2016 to 2022; about half occurred at EDs with lower pediatric volume, a national analysis found.
|Articles|February 5, 2008
FDA approves reduced-dose pediatric asthma inhaler
The Food and Drug Administration approved Schering-Plough's Asmanex Twisthaler (mometasone furoate inhalation powder) in a 110-mcg formulation, for preventative asthma therapy for children 4 to 11 years of age....
Advertisement
Advertisement
Related to this article
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older
3
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
4
Fenfluramine shows sustained seizure reduction, functional improvement in Lennox-Gastaut syndrome
5